NCT05412472View on ClinicalTrials.gov

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

January 30, 2021

Study Completion Date

April 6, 2021

Conditions
Renal Impairment
Interventions
DRUG

GC4419

45 mg IV infusion of GC4419 over 60 minutes.

Trial Locations (2)

33136

Inventiv Health Clinical -Research Pharmacy Unit, Miami

University of Miami Division of Clinical Pharmacology, Miami

Sponsors
All Listed Sponsors
lead

Galera Therapeutics, Inc.

INDUSTRY

NCT05412472 - Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419 | Biotech Hunter | Biotech Hunter